{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney+Cancers&page=34", "query": { "condition": "Kidney Cancers", "page": 34 }, "page_size": 10 }, "pagination": { "page": 34, "page_size": 10, "total_count": 1818, "total_pages": 182, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney+Cancers&page=35&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney+Cancers&page=33&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T21:16:08.010Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02793128", "title": "The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Transitional Cell", "Transitional Cell Carcinoma of Renal Pelvis" ], "interventions": [ { "name": "UGN-101 instillations", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UroGen Pharma Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2017-04-04", "completion_date": "2020-03-05", "has_results": true, "last_update_posted_date": "2020-12-22", "last_synced_at": "2026-11-15T21:16:08.010Z", "location_count": 22, "location_summary": "Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02793128" }, { "nct_id": "NCT01575925", "title": "Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Renal Impairment" ], "interventions": [ { "name": "4 mg Oral POM + 40 mg Oral DEX", "type": "DRUG" }, { "name": "2 mg Oral POM + 40 mg Oral DEX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2012-06-01", "completion_date": "2018-08-07", "has_results": false, "last_update_posted_date": "2022-11-04", "last_synced_at": "2026-11-15T21:16:08.010Z", "location_count": 7, "location_summary": "Denver, Colorado • Atlanta, Georgia • Harvey, Illinois + 4 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Harvey", "state": "Illinois" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01575925" }, { "nct_id": "NCT05293496", "title": "A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Castration-Resistant Prostatic Cancer", "Malignant Melanoma", "Pancreatic Ductal Carcinoma", "Hepatocellular Cancer", "Epithelial Ovarian Cancer", "Renal Cell Carcinoma" ], "interventions": [ { "name": "vobramitamab duocarmazine", "type": "BIOLOGICAL" }, { "name": "lorigerlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2022-04-19", "completion_date": "2025-08-26", "has_results": false, "last_update_posted_date": "2025-10-14", "last_synced_at": "2026-11-15T21:16:08.010Z", "location_count": 10, "location_summary": "Los Angeles, California • San Francisco, California • Sarasota, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05293496" }, { "nct_id": "NCT03685591", "title": "PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Neoplasms", "Prostate Neoplasms", "Neoplasms, Squamous Cell", "Melanoma", "Mesothelioma", "Pancreatic Neoplasms", "Colorectal Neoplasms", "Carcinoma, Renal Cell", "Liver Neoplasms" ], "interventions": [ { "name": "PF-06952229", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2018-10-04", "completion_date": "2022-03-30", "has_results": true, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-11-15T21:16:08.010Z", "location_count": 15, "location_summary": "Scottsdale, Arizona • Santa Monica, California • Boston, Massachusetts + 6 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03685591" }, { "nct_id": "NCT03329950", "title": "A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Non-small Cell Lung Cancer", "Breast Cancer", "Gastric Cancer", "Renal Cell Carcinoma", "Ovarian Cancer", "Cholangiocarcinoma", "Bladder Urothelial Carcinoma", "Pancreatic Adenocarcinoma", "Colorectal Cancer", "Esophageal Cancer", "Hepatic Cancer", "Head and Neck Cancer", "Primary Peritoneal Cancer", "Fallopian Tube Cancer", "Other Solid Tumors", "Diffuse Large B-cell Lymphoma (DLBCL)", "Mantle Cell Lymphoma", "Indolent B-cell Lymphomas", "Non-Hodgkin Lymphoma", "Follicular Lymphoma", "Lymphoplasmacytic Lymphoma", "Waldenstrom's Disease", "Marginal Zone Lymphoma", "Mucosa Associated Lymphoid Tissue", "Small Lymphocytic Leukemia" ], "interventions": [ { "name": "CDX-1140", "type": "DRUG" }, { "name": "CDX-301", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 132, "start_date": "2017-12-01", "completion_date": "2022-09-13", "has_results": false, "last_update_posted_date": "2024-03-28", "last_synced_at": "2026-11-15T21:16:08.010Z", "location_count": 11, "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Augusta, Georgia + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03329950" }, { "nct_id": "NCT04616560", "title": "Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Desmoplastic Small Round Cell Tumor", "Osteosarcoma", "Recurrent Desmoplastic Small Round Cell Tumor", "Recurrent Kidney Wilms Tumor", "Recurrent Osteosarcoma", "Refractory Desmoplastic Small Round Cell Tumor", "Refractory Wilms Tumor", "Wilms Tumor" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Trastuzumab Deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "12 Years to 39 Years" }, "enrollment_count": 55, "start_date": "2021-03-08", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-11-12", "last_synced_at": "2026-11-15T21:16:08.010Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04616560" }, { "nct_id": "NCT03602079", "title": "Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer", "HER2 Gene Mutation", "HER-2 Gene Amplification", "HER2 Positive Gastric Cancer", "Salivary Gland Cancer", "Salivary Gland Tumor", "Salivary Gland Carcinoma", "Salivary Gland Neoplasms", "Lung Cancer", "Colo-rectal Cancer", "Rare Diseases", "Solid Tumor", "Recurrent Gastric Cancer", "Recurrent Colon Cancer", "Recurrent Breast Cancer", "Head and Neck Cancer", "Head and Neck Carcinoma", "Bladder Cancer", "Cervical Cancer", "Liver Cancer", "Bile Duct Cancer", "Urologic Cancer", "Pancreatic Cancer", "Prostate Cancer", "Recurrent Prostate Cancer", "Rectal Cancer", "Recurrent Ovarian Carcinoma", "Recurrent Renal Cell Cancer", "Rectal Cancer Stage II", "Rectal Cancer Stage I", "Rectal Cancer Stage III", "Skin Cancer", "Mouth Cancer", "Lip Cancer Stage I", "Tongue Cancer", "Breast Neoplasm Malignant Primary", "Larynx Cancer", "Tonsil Cancer", "Palate Cancer", "Mucoepidermoid Carcinoma", "Primary Peritoneal Carcinoma", "Mucinous Adenocarcinoma Gastric", "Mucinous Breast Cancer Recurrent", "Cholangiocarcinoma" ], "interventions": [ { "name": "A166", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Klus Pharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2018-07-16", "completion_date": "2022-01-12", "has_results": false, "last_update_posted_date": "2023-08-03", "last_synced_at": "2026-11-15T21:16:08.010Z", "location_count": 10, "location_summary": "Sarasota, Florida • Boston, Massachusetts • Detroit, Michigan + 7 more", "locations": [ { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Lake Success", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT03602079" }, { "nct_id": "NCT03229083", "title": "Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Advanced Renal Cell Carcinoma" ], "interventions": [ { "name": "Carevive software", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2019-07-24", "completion_date": "2025-02-14", "has_results": true, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-11-15T21:16:08.010Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03229083" }, { "nct_id": "NCT07383441", "title": "Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Clear Cell Renal Cell Carcinoma", "Metastatic Clear Cell Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Axitinib", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Clostridium butyricum CBM 588 Probiotic Strain", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab and Recombinant Human Hyaluronidase", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo Administration", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 718, "start_date": "2026-06-05", "completion_date": "2034-01-31", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-11-15T21:16:08.010Z", "location_count": 41, "location_summary": "Fayetteville, Arkansas • Jonesboro, Arkansas • Rogers, Arkansas + 36 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Bloomington", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07383441" }, { "nct_id": "NCT01832922", "title": "BR in Patients With CLL With Comorbidities and/or Renal Dysfunction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2013-04", "completion_date": "2016-11-28", "has_results": false, "last_update_posted_date": "2018-03-30", "last_synced_at": "2026-11-15T21:16:08.010Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Lebanon, New Hampshire", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT01832922" } ] }